Francia Reyes Silva

Abstract 142: A universal multi-receptor NK cell platform engineered for synergistic combination with antibody and T-cell engager therapies.

Rafet Başar, Bin Liu, Nadima Uprety, Francia Reyes Silva et autres

Abstract Background: Monoclonal antibodies (mAbs) and T-cell engagers (TCEs) redirect immune effector cells toward malignant targets, yet their efficacy is often limited by patient T- and NK-cell dysfunction. Conventional CAR strategies target a single antigen, requiring new construct design, GMP production, and …

us (code pays fourni par la source)

Abstract 5197: Metabolically supercharged NK cells engineered with adenoviral E4ORF-1

Maliha Nuzhat Munir, Madison Moore, Silvia Tiberti, Rafet Başar et autres

Abstract Background: Chimeric antigen receptor (CAR) T and natural killer (NK) cells have achieved success in hematologic malignancies but show limited efficacy in solid tumors. A major barrier is the metabolically hostile solid tumor microenvironment (TME), where hypoxia, acidosis, and nutrient deprivation …

us (code pays fourni par la source)

Abstract 5199: uPAR-targeting CAR-NK cells enhance cytotoxicity against acute myeloid leukemia

Xingliang Guo, Nadima Uprety, Rejeena Shrestha, Francia Reyes Silva et autres

Abstract Background: Relapsed/refractory acute myeloid leukemia (AML) remains difficult to treat, highlighting the need for new therapies. NK cell-based immunotherapy offers potent antitumor activity with low risk of GVHD or severe CRS. The urokinase plasminogen activator receptor (uPAR), encoded by PLAUR, is …

us (code pays fourni par la source)

Abstract 4010: NK-TCR cells: A next-generation platform expanding NK-cell therapeutic potential

Nadima Uprety, Bin Liu, Rafet Başar, Rejeena Shrestha et autres

Abstract Background: Adoptive transfer of engineered natural killer (NK) cells has emerged as a promising strategy for solid and hematologic malignancies; however, the absence of a physiological T-cell receptor (TCR) limits the spectrum of antigens for targeting and prevents recognition of intracellular …

us (code pays fourni par la source)

Abstract 5206: Mitochondrial remodeling sustains CAR-NK stemness for superior tumor control

Silvia Tiberti, Madison Moore, Maliha Nuzhat Munir, Merve Dede et autres

Abstract Background: NK cell-based therapies are a promising off-the-shelf strategy for cancer treatment. Their inherent safety and lack of graft-versus-host disease make NK cells an attractive platform for CAR engineering, combining innate cytotoxicity with receptor specificity. However, clinical efficacy in solid tumors …

us (code pays fourni par la source)

Abstract 5204: CD5-directed CAR5/IL-15 NK cells as a therapeutic platform for T-cell malignancies

Rafet Başar, Sunil Acharya, Nadima Uprety, May Daher et autres

Abstract Background: Engineered NK cells have increasingly emerged as a powerful allogeneic cell therapy platform, with multiple trials demonstrating meaningful anti-tumor responses, durable clinical activity, and an excellent safety profile without GVHD and low cytokine-release toxicity. Their suitability for large-scale manufacturing makes …

us (code pays fourni par la source)

Role of BK Virus CTLs in the Treatment of BK Virus–Associated Nephropathy in Kidney‐Transplant and Hematopoietic Cell Transplant Recipients

Amanda Leigh Olson, Ye Ethan Li, Rafet Başar, Pinaki Prosad Banerjee et autres

BACKGROUND: BK virus infection is a marker of poor immune recovery, especially after kidney or allogeneic cell transplantation. Because of the challenges associated with BK virus infection and the lack of effective treatments, there is a growing interest in novel approaches, such …

us (code pays fourni par la source)

Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency

Alexander Biederstädt, Rafet Başar, Jeong-Min Park, Nadima Uprety et autres

Adoptive cell therapy using engineered natural killer (NK) cells is a promising approach for cancer treatment, with targeted gene editing offering the potential to further enhance their therapeutic efficacy. However, the spectrum of actionable genetic targets to overcome tumor and microenvironment-mediated immunosuppression …

us (code pays fourni par la source)

Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Yago L. Nieto, Pinaki Prosad Banerjee, Indreshpal Kaur, Rafet Başar et autres

us, de (code pays fourni par la source)

CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells

Hind Rafei, Rafet Başar, Sunil Acharya, Yu-Sung Hsu et autres

Chimeric antigen receptor (CAR) natural killer (NK) cell immunotherapy offers a promising approach against cancer1–3. However, the molecular mechanisms that regulate CAR-NK cell activity remain unclear. Here we identify the transcription factor cyclic AMP response element modulator (CREM) as a crucial regulator …

us, de (code pays fourni par la source)

Abstract 6396: CREM is a regulatory checkpoint of CAR and IL-15 signaling in NK cells

Hind Rafei, Rafet Başar, Sunil Acharya, Yu-Sung Hsu et autres

Abstract Chimeric antigen receptor (CAR) natural killer (NK) cell immunotherapy offers a promising approach against cancer. However, the molecular mechanisms governing CAR NK cell activity remain poorly understood. In this study, we identified the transcription factor cAMP response element modulator (CREM) as …

us (code pays fourni par la source)

Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Yago L. Nieto, Pinaki Prosad Banerjee, Indreshpal Kaur, Rafet Başar et autres

us, de (code pays fourni par la source)